A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.
Dado Ruvic | Reuters
Biogen on Wednesday posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer’s treatment Leqembi, saw growth.Â
But the biotech company’s guidance for the current year missed Wall Street’s expectations. Biogen issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the $16.34 per share that analysts were anticipating, according to LSEG. That reflects a foreign exchange headwind of 35 cents per share, Biogen said. Â
Biogen expects revenue to decline by a “mid-single digit” percentage in 2025 compared with 2024, as sales of its multiple sclerosis products fall. That portion of the business has declined for several quarters as some of those therapies face generic…
